Aruvant’s Eleven New Hires Advance its Internal-External Supply Model Strategy to Manufacture Gene Therapies for Rare Diseases
NEW YORK and BASEL, Switzerland, May 4, 2021 — Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in...
Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting
--Data demonstrates treatment with ARU-1801 resulted in meaningful improvements in clinical outcomes for participants with severe sickle cell disease-- NEW YORK and BASEL, Switzerland, Apr. 27, 2021 — Aruvant Sciences (“Aruvant”), a private company focused on...
Aruvant Appoints Meghan Kelton Executive Director of Human Resources and E. Blair Clark-Schoeb Senior Vice President of Communications
NEW YORK and BASEL, Switzerland, Apr. 23, 2021 — Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan Kelton, executive...
Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March
NEW YORK and BASEL, Switzerland, Feb. 11, 2021 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced management participation in multiple...
Aruvant Announces the European Medicines Agency (EMA) Granted Priority Medicines (PRIME) Designation to ARU-1801 for the Treatment of Sickle Cell Disease
New York, NY, Feb. 3, 2021 –Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to ARU-1801, a one-time investigational gene...
Aruvant Chooses Lonza to Manufacture ARU-1801, a Potentially Curative Treatment for Sickle Cell Disease, for Pivotal Trial
New York, NY, Jan. 18, 2021 –Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD)....
Aruvant’s Data Presented in Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Demonstrates Promise of ARU-1801 as a Potentially Curative Treatment for Sickle Cell Disease
–Data from improved manufacturing process resulted in significantly improved ARU-1801 product profile– New York, NY, Dec. 7, 2020 – Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, announced new data demonstrating the...
Aruvant to Participate in SVB Leerink’s Biopharma Private Company Connect December 15 to 17
NEW YORK and BASEL, Switzerland, Dec. 1, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced Will Chou, M.D., Aruvant chief executive...